$TMO

Generating a unique summary for TMO…

AI-generated for information only — not investment advice.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Institutions hold 94.19% · insiders 0.13% · 3,563 institutions

Consensus score 1.59 (1 = strong buy, 5 = sell) · mean target 638.11

• CLSAOutperforminit2026-09-03
• Piper SandlerNeutralmain2026-07-27
• Morgan StanleyOverweightmain2026-07-27
• RBC CapitalSector Performmain2026-07-24
• BarclaysOverweightmain2026-07-24
• Evercore ISI GroupOutperformmain2026-07-06
• Piper SandlerNeutralinit2026-06-11
• HSBCHolddown2026-06-03
• Wells FargoOverweightmain2026-05-08
• StifelBuymain2026-04-24

Next report: 2026-10-21

• 10-QPeriodic Financial Reports2026-07-31Open
• 8-KCorporate Changes & Voting Matters2026-07-23Open
• 11-KAnnual report of employee stock purchase2026-06-23Open
• SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-05-28Open
• 8-KCorporate Changes & Voting Matters2026-05-26Open
• DEFA14AProxy Statements2026-05-11Open
• 10-QPeriodic Financial Reports2026-05-01Open
• 8-KCorporate Changes & Voting Matters2026-04-23Open
• ARSAnnual Report to Shareholders2026-04-07Open
• 8-KCorporate Changes & Voting Matters2026-03-24Open

• Veterinary Diagnostic Markets Report Now Available — See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030

  249-Page Report Delivers Country-by-Country Forecasts Across 15 Markets, Competitive Profiles of 32 Companies, and the Investment-Grade Data You Need to Act With ConfidenceDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Veterinary Diagnostic Markets. Strategy & Trends with Forecasts by Assay Type, by Animal, by Application, by Place, by Product, and by Country 2026 to 2030" report has been added to ResearchAndMarkets.com's offering. The Veterinary Diagnostics industry is on a strong growth path

  Mon, 07 Sep 2026 10:38:00 +0000

• Should You Continue to Hold TMO Stock in Your Portfolio?

  Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.

  Fri, 04 Sep 2026 14:35:00 +0000

• 1 Healthcare Stock for Long-Term Investors and 2 We Ignore

  Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 23.2% over the past six months, topping the S&P 500 by 11.5 percentage points.

  Fri, 04 Sep 2026 10:06:10 +0000

• ‘Corporate America Is Basically Exterminating Your Career.” Clark Howard’s Sounds Alarm For Americans In Their 50s, Who Want To Work Till 65

  Clark Howard named a specific age when corporate America tends to push workers out, and it falls years before most people's retirement plans even begin to account for income gaps, portfolio shortfalls, or Social Security decisions.

  Fri, 04 Sep 2026 13:35:32 +0000

• Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share

  The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher

  Fri, 04 Sep 2026 09:48:00 +0000

• Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More

  Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.

  Thu, 03 Sep 2026 12:05:46 +0000

• PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test

  PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.

  Wed, 02 Sep 2026 17:55:00 +0000

• Here's Why You Should Add Merit Medical Stock to Your Portfolio Now

  MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.

  Wed, 02 Sep 2026 15:31:00 +0000